Chromosome Aberrations

"Chromosome Aberrations" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Abnormal number or structure of chromosomes. Chromosome aberrations may result in CHROMOSOME DISORDERS.

Descriptor ID	D002869
MeSH Number(s)	C23.550.210 G05.365.590.175
Concept/Terms	Chromosome Aberrations Chromosome Aberrations Aberration, Chromosome Aberrations, Chromosome Chromosome Aberration Abnormalities, Chromosome Abnormality, Chromosome Chromosome Abnormality Cytogenetic Abnormalities Abnormalities, Cytogenetic Abnormality, Cytogenetic Cytogenetic Abnormality Chromosome Abnormalities Cytogenetic Aberrations Aberration, Cytogenetic Aberrations, Cytogenetic Cytogenetic Aberration Abnormalities, Chromosomal Abnormality, Chromosomal Chromosomal Abnormalities Chromosomal Abnormality Chromosomal Aberrations Aberration, Chromosomal Aberrations, Chromosomal Chromosomal Aberration Autosome Abnormalities Autosome Abnormalities Abnormality, Autosome Autosome Abnormality Abnormalities, Autosome

Below are MeSH descriptors whose meaning is more general than "Chromosome Aberrations".

Diseases [C]
Pathological Conditions, Signs and Symptoms [C23]
Pathologic Processes [C23.550]
Chromosome Aberrations [C23.550.210]
Biological Sciences [G]
Genetic Phenomena [G05]
Genetic Variation [G05.365]
Mutation [G05.365.590]
Chromosome Aberrations [G05.365.590.175]

Below are MeSH descriptors whose meaning is related to "Chromosome Aberrations".

Below are MeSH descriptors whose meaning is more specific than "Chromosome Aberrations".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Chromosome Aberrations" by people in this website by year, and whether "Chromosome Aberrations" was a major or minor topic of these publications.

Bar chart showing 51 publications over 23 distinct years, with a maximum of 6 publications in 2007

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1996	0	1	1
1998	0	1	1
2000	1	2	3
2001	1	0	1
2002	0	1	1
2003	1	1	2
2006	0	1	1
2007	4	2	6
2008	1	1	2
2009	1	0	1
2010	0	2	2
2012	1	1	2
2013	2	1	3
2014	1	2	3
2015	2	2	4
2016	2	2	4
2017	1	1	2
2019	2	0	2
2020	1	1	2
2021	1	1	2
2023	0	1	1
2024	0	2	2
2025	0	3	3

Below are the most recent publications written about "Chromosome Aberrations" by people in Profiles.

Maura F, Kaddoura M, Poos AM, Baughn LB, Ziccheddu B, B?rtsch MA, Cirrincione A, Maclachlan K, Chojnacka M, Diamond B, Papadimitriou M, Blaney P, John L, Reichert P, Huhn S, Gagler D, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Rajkumar SV, Kumar S, Usmani S, Landgren O, Raab MS, Weinhold N. Temporal genomic dynamics shape clinical trajectory in multiple myeloma. Nat Genet. 2025 Sep; 57(9):2203-2214.

View in: PubMed
Lu X, Andersen EF, Banerjee R, Eno CC, Gonzales PR, Kumar S, Lager AM, Miron PM, Pugh T, Quintero-Rivera F, Thurston VC, Wolff DJ, Zhao J, Fonseca R, Baughn LB. Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group. Blood Cancer J. 2025 Jun 18; 15(1):86.

View in: PubMed
Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Pr?sper F, Munshi NC. International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025 Aug 20; 43(24):2739-2751.

View in: PubMed
Cirrincione AM, Poos AM, Ziccheddu B, Kaddoura M, B?rtsch MA, Maclachlan K, Chojnacka M, Diamond B, John L, Reichert P, Huhn S, Blaney P, Gagler D, Rippe K, Zhang Y, Dogan A, Lesokhin AM, Davies F, Goldschmidt H, Fenk R, Weisel KC, Mai EK, Korde N, Morgan GJ, Usmani S, Landgren O, Raab MS, Weinhold N, Maura F. The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma. Blood. 2024 08 15; 144(7):771-783.

View in: PubMed
Callander NS, Silbermann R, Kaufman JL, Godby KN, Laubach J, Schmidt TM, Sborov DW, Medvedova E, Reeves B, Dhakal B, Rodriguez C, Chhabra S, Chari A, Bal S, Anderson LD, Dholaria BR, Nathwani N, Hari P, Shah N, Bumma N, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Pei H, Cortoos A, Patel S, Lin TS, Giri S, Costa LJ, Usmani SZ, Richardson PG, Voorhees PM. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 04 22; 14(1):69.

View in: PubMed
Tucker SM, Zaihra T. Cytogenetic and survival analysis in 315 multiple myeloma patients; five with orbital and eight with extramedullary disease. Orbit. 2023 Dec; 42(6):603-611.

View in: PubMed
Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, And?jar-S?nchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021 11 18; 81(22):4692-4708.e9.

View in: PubMed
Schmidt TM, Fonseca R, Usmani SZ. Chromosome 1q21 abnormalities in multiple myeloma. Blood Cancer J. 2021 04 29; 11(4):83.

View in: PubMed
Softness KA, Trussler JT, Carrasquillo RJ. Advanced sperm testing. Curr Opin Urol. 2020 05; 30(3):290-295.

View in: PubMed
Miron PM, Fang M. The evolving clinical testing landscape of genomic aberrations in solid tumors and hematological malignancies - Insights from evidence-based reviews for B-ALL and breast, brain, and renal cell neoplasia. Cancer Genet. 2020 06; 244:60-61.

View in: PubMed

People

Explore

Similar Concepts

Top Journals